undefined undefined
NaN.000
NaN.00%
Gainers: Oportun Financial (OPRT) +5%. Humacyte (HUMA) +2%. Revance Therapeutics (RVNC) +2%. Office Properties Income (OPI) +2%. Axcelis Technologies (ACLS) +1%. Losers: Cadence Design Systems (CDNS...
04-23 04:53
Oppenheimer analyst Jeff Jones reiterates AN2 Therapeutics (NASDAQ:ANTX) from Perform to Perform.
04-01 21:13
AN2 Therapeutics press release (NASDAQ:ANTX): Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. R&D expenses for the full year 2023 were $54.9 million, co...
03-29 05:11
Bubonic plague, responsible for the Black Death that ravaged Europe and Asia in the mid-1300s, is transmitted to humans through flea bites or contact with infected animals.
02-15 19:14
U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The S&P 500 also rose, gaining, 0.12% to 5,032.46.
02-13 03:15
Oppenheimer analyst Jeff Jones downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Perform.
02-13 00:54
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.05% to 38,651.80 while the NASDAQ rose 0.09% to 16,004.39. The S&P 500 also rose, gaining, 0.01% to 5,026.74.
02-12 22:51
AN2 Therapeutics pauses Phase 3 enrollment for epetraborole trial in Mycobacterium Avium Complex lung disease. Updates expected in summer 2024.
02-12 22:08
千亿巨头最新持仓曝光!加仓网易,减持拼多多;美联储官员将“扎堆”讲话;英伟达进军芯片定制业务,盘前涨近1%>>
02-12 21:33